Podcast

Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer

Author(s):

OncLive Staff

In Partnership With:

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

Welcome to OncLive On Air™! I’m your host today, Jessica Hergert.

OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Bristol Myers Squibb, we had the pleasure of speaking with Estelamari Rodriguez, MD, MPH, associate director of Community Outreach at Sylvester Comprehensive Cancer Center within the University of Miami Health System, to discuss the history of immuno-oncology in thoracic oncology.

In our exclusive interview, Rodriguez discussed historic treatments in lung cancer that preceded the integration of immunotherapy, shared current treatment selection and sequencing strategies, and forecasted the future of immunotherapy in the field.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
C. Ola Landgren, MD, PhD
Justin M. Watts, MD
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology
July 26th 2024

CHMP Recommends Amivantamab Plus Chemo for Pretreated EGFR+ Advanced NSCLC

David Miller, MD, professor, chief, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Amy and Vernon R. Faulconer Distinguished Chair in Gynecologic Oncology, University of Texas (UT) Southwestern Medical School; medical director, UT Southwestern Harold C. Simmons Cancer Center
July 25th 2024

Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

Jonathan W. Riess, MD, MS
July 26th 2024

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

ODAC Votes to Require Within Trial Assessment of Neoadjuvant vs Adjuvant Treatment Benefit in Perioperative Trial Protocols in Resectable NSCLC
July 25th 2024

ODAC Votes to Require Within Trial Assessment of Neoadjuvant vs Adjuvant Treatment Benefit in Perioperative Trial Protocols in Resectable NSCLC

Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy